BioSpace News Archive

Ambyint and Equinor announced that Equinor will deploy Amybint’s technology on all rod pump wells in Equinor’s Bakken asset in North Dakota.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced that it has signed a purchase and sale agreement for the acquisition of a 135,000-square foot manufacturing facility located in Smithfield, Rhode Island.

Glenmark is seeking use of GBR 310 for the same indications as the reference biologic for the treatment of allergic asthma and chronic idiopathic urticaria (CIU)

Evolent Health, Inc. announced that Chief Executive Officer & Co-Founder Frank Williams and Chief Financial Officer Nicky McGrane will participate in an upcoming investor conference.

President Trump Wants to Reduce Patient Out-of-Pocket Costs. BeneCard PBF’s Expert Clinical Care Coordination Improves Patient Safety and Reduces Costs by Combatting Inappropriate Prescribing.

Eisai Co., Ltd. and Biogen Inc. announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) at the Alzheimer’s Association International Conference (AAIC) 2018

Saladax is Advancing Personalized Medicine by Providing Psychiatrists with the New MyCare Line of Assays to Improve Patient Treatment.

$50,000 grant awarded during HealthTrust University Conference

PathogenDx Corporation announced that company executives Milan Patel, Co-Founder and Chief Executive Officer; Jeff Ryskamp, Chief Financial Officer; Mary Myers, National Sales Director and Magdalena Kedzior, Scientist/Technical Trainer will be available at Booth #1519 at NCIA’s 5th Annual Cannabis Business & Expo in San Jose

Digital Pharmacist Inc. announced that an additional one thousand five hundred pharmacies have adopted its platform in the past 12 months.